Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide-associated hepatitis: a case report.

R Fowler1, K Imrie

  • 1Department of Medical Oncology and Hematology, Toronto-Sunnybrook Regional Cancer Centre, Faculty of Medicine, University of Toronto, Toronto, Canada.

American Journal of Hematology
|April 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antifoams in non-aqueous diesel fuels: Thin liquid film dynamics and antifoam mechanisms.

Journal of colloid and interface science·2024
Same author

Choosing wisely in burn care.

Burns : journal of the International Society for Burn Injuries·2021
Same author

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.

Clinical oncology (Royal College of Radiologists (Great Britain))·2016
Same author

Bortezomib in multiple myeloma: systematic review and clinical considerations.

Current oncology (Toronto, Ont.)·2014
Same author

The use of hypnosis for pain relief for patients with polyradiculoneuritis.

The Australian journal of physiotherapy·2014
Same author

Bortezomib in multiple myeloma: a practice guideline.

Clinical oncology (Royal College of Radiologists (Great Britain))·2013
Same journal

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

American journal of hematology·2026
Same journal

Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL.

American journal of hematology·2026
Same journal

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

American journal of hematology·2026
Same journal

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

American journal of hematology·2026
Same journal

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

American journal of hematology·2026
Same journal

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

American journal of hematology·2026
See all related articles

This case study highlights a rare instance of thalidomide-induced hepatitis in a patient with plasma cell leukemia. The liver injury resolved after discontinuing thalidomide, suggesting a potential hepatotoxic effect of this drug.

Area of Science:

  • Hepatology
  • Hematology
  • Pharmacology

Background:

  • Plasma cell leukemia is a hematologic malignancy.
  • Thalidomide is increasingly used for plasma cell leukemia.
  • Hepatitis C infection was a pre-existing condition.

Observation:

  • A 58-year-old woman with refractory plasma cell leukemia was treated with thalidomide.
  • Within one week of treatment, she developed jaundice and elevated liver enzymes.
  • These symptoms resolved upon thalidomide cessation.

Findings:

  • This is the first reported case of thalidomide-associated hepatotoxicity.
  • The exact mechanism of liver injury is uncertain.
  • Possible mechanisms include direct hepatotoxicity or immune modulation of chronic hepatitis C.

Related Experiment Videos

Implications:

  • Clinicians should be aware of potential thalidomide-induced liver injury.
  • Monitoring liver function is crucial in patients receiving thalidomide.
  • Further research is needed to elucidate the mechanism of thalidomide hepatotoxicity.